GoAI
Get started
Eiken Chemical Co., Ltd. logo

Eiken Chemical Co., Ltd.

4549.T

JPXHealthcareMedical - Devices

Open in GoAI

Latest quote

¥2,346

−¥32.00 · -1.35%

Aug 24, 3:30 PM JST

4549.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Eiken Chemical Co., Ltd. is a Japanese manufacturer and distributor specializing in clinical diagnostic products and medical equipment. The company excels in developing diagnostic solutions for diverse medical fields, encompassing biochemical analysis, immunology, serology, dry chemical assays, and automated diagnostic systems. A significant offering is the OC-SENSOR, an automated immunochemical fecal test designed to identify gastrointestinal bleeding linked to conditions such as colorectal cancer, polyps, and diverticulitis. Its comprehensive product portfolio further includes real-time turbidimeters, temperature-controlled equipment, various amplification and fluorescence detection reagents for research applications, and general detection kits. Eiken Chemical also produces a variety of microbiology-related products, alongside additional immunological and serological reagents. Established in Tokyo, Japan, in 1939, the company initially operated as Nihon Eiyokagaku Co., Ltd. until its rebranding to Eiken Chemical Co., Ltd. in 1969.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
JP
CEO
Yuji Segawa
Listed since
Jan 4, 2001
Employees
696

Market position

Day range

Current ¥2,346

52-week range

Current ¥2,346

Open
¥2,358
Previous close
¥2,378
Volume
239.6K
1.23× average
Average volume
195.48K
Average daily volume
Market cap
77.34B JPY
Beta
0.74
Market reference 1
50-day average
¥2,475.52
-5.23% below average
200-day average
¥2,677.51
-12.38% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
97.04B JPY
P/E (TTM)
21.76×
P/B (TTM)
1.78×
P/S (TTM)
1.82×
EV / EBITDA
17.78×
Earnings yield
3.68%
Free cash flow yield
-1.71%
Dividend yield
2.47%

Profitability & efficiency

Gross margin
38.07%
Operating margin
6.57%
Net margin
8.37%
Return on equity
8.42%
Return on assets
5.92%
Return on invested capital
4.33%

Financial health

Debt / equity
0.14×
Current ratio
2.19×
Altman Z-score
4.52
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends52%35%18%1%Gross margin, FY2021: 47.84%Gross margin, FY2022: 47.39%Gross margin, FY2023: 41.76%Gross margin, FY2024: 40.73%Gross margin, FY2025: 38.61%Operating margin, FY2021: 19.50%Operating margin, FY2022: 17.23%Operating margin, FY2023: 8.43%Operating margin, FY2024: 7.40%Operating margin, FY2025: 6.97%Net margin, FY2021: 14.46%Net margin, FY2022: 13.26%Net margin, FY2023: 6.58%Net margin, FY2024: 5.50%Net margin, FY2025: 8.85%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 47.84%. Gross margin FY2022 47.39%. Gross margin FY2023 41.76%. Gross margin FY2024 40.73%. Gross margin FY2025 38.61%. Operating margin FY2021 19.50%. Operating margin FY2022 17.23%. Operating margin FY2023 8.43%. Operating margin FY2024 7.40%. Operating margin FY2025 6.97%. Net margin FY2021 14.46%. Net margin FY2022 13.26%. Net margin FY2023 6.58%. Net margin FY2024 5.50%. Net margin FY2025 8.85%.

Income trends

Revenue

41.9B JPY+3.35%

Operating income

2.92B JPY-2.63%

Net income

3.71B JPY+66.43%
Income trends across reported periods47.38B JPY30.96B JPY14.54B JPY−1.88B JPYRevenue, FY2021: 43B JPYRevenue, FY2022: 43.27B JPYRevenue, FY2023: 40.05B JPYRevenue, FY2024: 40.54B JPYRevenue, FY2025: 41.9B JPYOperating income, FY2021: 8.39B JPYOperating income, FY2022: 7.46B JPYOperating income, FY2023: 3.38B JPYOperating income, FY2024: 3B JPYOperating income, FY2025: 2.92B JPYNet income, FY2021: 6.22B JPYNet income, FY2022: 5.74B JPYNet income, FY2023: 2.63B JPYNet income, FY2024: 2.23B JPYNet income, FY2025: 3.71B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 43B JPY. Revenue FY2022 43.27B JPY. Revenue FY2023 40.05B JPY. Revenue FY2024 40.54B JPY. Revenue FY2025 41.9B JPY. Operating income FY2021 8.39B JPY. Operating income FY2022 7.46B JPY. Operating income FY2023 3.38B JPY. Operating income FY2024 3B JPY. Operating income FY2025 2.92B JPY. Net income FY2021 6.22B JPY. Net income FY2022 5.74B JPY. Net income FY2023 2.63B JPY. Net income FY2024 2.23B JPY. Net income FY2025 3.71B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue41.9B JPY40.54B JPY40.05B JPY43.27B JPY43B JPY
Cost of goods sold25.72B JPY24.03B JPY23.33B JPY22.77B JPY22.43B JPY
Gross profit16.18B JPY16.51B JPY16.72B JPY20.51B JPY20.57B JPY
Research and development3.68B JPY4.39B JPY3.94B JPY4.07B JPY3.41B JPY
Selling, general, and administrative9.58B JPY9.13B JPY9.41B JPY8.98B JPY8.78B JPY
Operating expenses13.26B JPY13.51B JPY13.35B JPY13.05B JPY12.18B JPY
Interest income17M JPY14M JPY8M JPY15M JPY18M JPY
Interest expense29M JPY17M JPY17M JPY16M JPY29M JPY
Depreciation and amortization2.54B JPY2.55B JPY2.33B JPY2.13B JPY2.06B JPY
Operating income2.92B JPY3B JPY3.38B JPY7.46B JPY8.39B JPY
Net income3.71B JPY2.23B JPY2.63B JPY5.74B JPY6.22B JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
13.52

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates78.0349.9421.86-6.23Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Oct 31, 2024: actual 23.77, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Jan 31, 2025: actual 23.39, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 13, 2025: actual 3.59, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Jul 31, 2025: actual 18.21, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Oct 30, 2025: actual 72.22, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Jan 30, 2026: actual 22.51, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual -0.42, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Jul 30, 2026: actual 13.52, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates11.65B10.91B10.16B9.42BQ4 '24MissQ1 '25MetQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MetQ2 '26BeatQ3 '26Beat
Q4 2024, reported Oct 31, 2024: actual 10.21B JPY, estimate 11.2B JPY, surprise -8.84%, Miss. Q1 2025, reported Jan 31, 2025: actual 10.91B JPY, estimate 10.91B JPY, surprise 0.00%, Met estimate. Q2 2025, reported May 13, 2025: actual 9.9B JPY, estimate 10.04B JPY, surprise -1.40%, Miss. Q3 2025, reported Jul 31, 2025: actual 10.2B JPY, estimate 10.05B JPY, surprise +1.51%, Beat. Q4 2025, reported Oct 30, 2025: actual 10.23B JPY, estimate 10.82B JPY, surprise -5.41%, Miss. Q1 2026, reported Jan 30, 2026: actual 10.95B JPY, estimate 10.95B JPY, surprise 0.00%, Met estimate. Q2 2026, reported May 12, 2026: actual 10.52B JPY, estimate 9.87B JPY, surprise +6.60%, Beat. Q3 2026, reported Jul 30, 2026: actual 10.73B JPY, estimate 10.2B JPY, surprise +5.19%, Beat.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

¥56.00

2025 complete year+36.6% since 2021

2026 partial: ¥29.00

* Partial calendar year in the available dividend history.

Corporate action history

DividendUpcoming

Ex-dividend Sep 29, 2026

¥29.00

Semi-Annual

Record Sep 30, 2026 · Payment Sep 29, 2026

DividendUpcoming

Ex-dividend Mar 31, 2027

¥29.00

Semi-Annual

Record Mar 31, 2027 · Payment Mar 31, 2027

Dividend

Ex-dividend Mar 30, 2026

¥29.00

Semi-Annual

Record Mar 31, 2026 · Payment Jun 9, 2026

Dividend

Ex-dividend Sep 29, 2025

¥29.00

Semi-Annual

Record Sep 30, 2025 · Payment Dec 1, 2025

Dividend

Ex-dividend Mar 28, 2025

¥27.00

Semi-Annual

Record Mar 31, 2025 · Payment Jun 6, 2025

Dividend

Ex-dividend Sep 27, 2024

¥26.00

Semi-Annual

Record Sep 30, 2024 · Payment Dec 2, 2024

4549.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,973

-0.54%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,815

+0.88%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,975

+0.32%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,205

+0.08%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,862

+1.01%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406

+0.80%

ETFs holding 4549.T

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core TOPIX ETF logoiShares Core TOPIX ETF1475.T
Market value
172.17M
Weight
0.01%
AUM
2.89T JPY
Expense ratio
0.05%
Price / 1D
¥417.7-0.07%
Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
5.97M
Weight
0.00%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$87.71+0.78%
Vanguard FTSE Developed Markets ETF logoVanguard FTSE Developed Markets ETFVEA
Market value
4.24M
Weight
0.00%
AUM
315B USD
Expense ratio
0.03%
Price / 1D
$73.42+0.80%
iShares Core MSCI EAFE ETF logoiShares Core MSCI EAFE ETFIEFA
Market value
2.23M
Weight
0.00%
AUM
195.14B USD
Expense ratio
0.07%
Price / 1D
$100.85+0.86%
iShares MSCI EAFE Small-Cap ETF logoiShares MSCI EAFE Small-Cap ETFSCZ
Market value
1.71M
Weight
0.01%
AUM
13.28B USD
Expense ratio
0.40%
Price / 1D
$86.60+0.70%
WisdomTree Japan Hedged Equity Fund logoWisdomTree Japan Hedged Equity FundDXJ
Market value
1.62M
Weight
0.02%
AUM
7.11B USD
Expense ratio
0.48%
Price / 1D
$177.54+1.10%
Vanguard FTSE All-World ex-US Small-Cap ETF logoVanguard FTSE All-World ex-US Small-Cap ETFVSS
Market value
1.62M
Weight
0.01%
AUM
13.6B USD
Expense ratio
0.06%
Price / 1D
$160.06+0.43%
Schwab International Small-Cap Equity ETF logoSchwab International Small-Cap Equity ETFSCHC
Market value
1.05M
Weight
0.02%
AUM
5.73B USD
Expense ratio
0.06%
Price / 1D
$51.25+0.61%

Continue in GoAI

Research 4549.T

research.disclaimer